Arrowhead presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3
The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3